PTLA News and Press, Portola Pharmaceuticals Inc.

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Merger activity remained steady last week with one new deal announced, six deals closing and one deal called off. The month of June ended with six active deals being completed and another deal terminated, resulting in a total of five deals terminated in a single month. June was also the most...

Alexion Pharmaceuticals (NASDAQ: ALXN ) has completed its acquisition of Portola Pharmaceuticals (NASDAQ: PTLA ), through a tender offer and merger with its subsidiary, Odyssey Merger Sub Inc. (“Buyer”). More news on: Alexion Pharmaceuticals, Inc., Portola Pharmaceutic...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Investment Thesis The patent disputes over its leading revenue generator have taken its toll on Alexion Pharmaceuticals, Inc. ( ALXN ), with its share price lagging the peers as the company attempts to diversify the top-line. The recent acquisitions, driven by the rising cash flows and low...

SOUTH SAN FRANCISCO, Calif. , May 18, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and othe...

Merger activity sputtered to a stop again last week with no new deals announced and one deal closing. This is the fifth week this year with no new deals announced. There were however some potential deals that were announced last week. On Monday, May 11, 2020, according to Bloomberg, Amazon.c...

Portola Pharmaceuticals (NASDAQ: PTLA ) is a $1.4 billion corporation that was recently acquired by Alexion Pharmaceuticals (NASDAQ: ALXN ). The two companies entered a definitive merger agreement, which we discussed and recommend reading about here . As we'll see throughout this article, r...

Alexion Pharmaceuticals (NASDAQ: ALXN ) is a more than $20 billion company that has announced it is acquiring Portola Pharmaceuticals (NASDAQ: PTLA ) for $1.45 billion. That represents an acquisition worth almost 8% of the company’s market capitalization. Given Alexion Pharmaceuticals...

SOUTH SAN FRANCISCO, Calif. , May 14, 2020 /PRNewswire/ -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has proposed extending the New Technology Add-on Payment (NTAP) for Andexxa ®  [coagula...